Beyond erectile dysfunction: Optimization of vardenafil dihydrochloride for hepatic encephalopathy prophylaxis using hybrid lipid polymeric nanoparticles formulation
Loading...
Date
2025-03-06
Journal Title
Journal ISSN
Volume Title
Type
Article
Publisher
Editions de Sante
Series Info
Journal of Drug Delivery Science and Technology ; Volume 107 , May 2025 , Article number 106787
Scientific Journal Rankings
Abstract
Vardenafil dihydrochloride (VD), a phosphodiesterase-5 (PDE5) is widely used to treat erectile dysfunction, but
recent studies suggested its potential for other diseases such as hepatic encephalopathy. However, VD suffers
poor solubility and oral bioavailability, and significant first-pass metabolism. This study aims to enhance the
bioavailability of VD by employing two combined approaches: formulation of VD into hybrid lipid-polymeric
nanoparticles (HLPNPs), and incorporating piperine, a known bioavailability enhancer, to investigate its potential in preventing hepatic encephalopathy. HLPNPs were developed using homogenization/ultrasonication
technique, with a one-factor design testing chitosan, oleic acid, or sodium alginate as the helper polymers. Oleic
acid showed the best results and was used to prepare the optimized formula (O1), which had a particle size of 128
± 2.8 nm, a polydispersity index of 0.173 ± 0.07, an entrapment efficiency of 93 ± 1.8 %, and a zeta potential of
− 32 ± 1.67 mV. O1 showed a sustained drug release profile, with approximately 70 % of VD released over 72 h.
O2 was then prepared with the addition of piperine, resulting in a longer residence time of 717 min compared to
O1 (94 min) in the pharmacokinetics study. O1 showed a twofold increase in the bioavailability compared to the
unformulated VD while O2 exhibited a ninefold increase. The improvement was confirmed by the higher Cmax
from 9 ng/mL for standard VD to 13 ng/mL and 22 ng/mL for O1 and O2, respectively. In hepatic
encephalopathy-induced mice model, O2 showed promising efficacy, with significant improvements in liver
enzymes, ammonia levels, hippocampal BDNF levels, cGMP levels, and hippocampal GluR1 and P-CREB levels.
These findings suggest that combining VD into HLPNPs with piperine is an effective strategy to overcome its
bioavailability limitations and enhance its therapeutic potential.
Description
SJR 2024
0.817 Q1
H-Index
89
Keywords
Enhanced bioavailability, Hepatic encephalopathy, Optimization, Repurposing, Vardenafil dihydrochloride
Citation
Dawoud, M. H., Elbalkiny, H. T., Gharib, Y. E., Fakkar, S. A., Saber, R., Yanni, M. E., & Zaafan, M. A. (2025b). Beyond Erectile Dysfunction: Optimization of Vardenafil Dihydrochloride for Hepatic Encephalopathy Prophylaxis using Hybrid Lipid Polymeric Nanoparticles Formulation. Journal of Drug Delivery Science and Technology, 106787. https://doi.org/10.1016/j.jddst.2025.106787